MERCK KGAA raised its 2026 adjusted EBITDA guidance to a range of 5.7 billion euros to 6.1 billion euros. The previous forecast for the pharmaceuticals giant based in Germany spanned 5.5 billion euros to 6.0 billion euros. The revised midpoint of 5.9 billion euros exceeds the 5.8 billion euros consensus estimate analysts previously projected for 2026.

Life Science and Mavenclad Drive Growth